Gilead Bets on Pharmasset with US$11 B Acquisition Agreement
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 12 (Table of Contents)
Published: 12 Dec-2011
DOI: 10.3833/pdr.v2011.i12.1636 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Gilead Sciences, the leading player in the HIV therapy market, has agreed to purchase Pharmasset for approximately US$11 B in order to advance its endeavours to develop an all-oral, interferon-free treatment regimen for hepatitis C virus (HCV) infection...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS